Slingshot members are tracking this event:

Novartis' (NVS) Gets Priority Review for Ribociclib Marketing Application in First-Line Treatment of HR+/HER2- Advanced Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 01, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Priority Review, Ribociclib, Marketing Application, First-line Treatment, Hr+/her2- Advanced Breast Cancer